The serotonin transporter (SERT) belongs to a family of sodium chloride-dependent transporters responsible for uptake of amino acids and biogenic amines from extracellular spaces. SERT represents the main pharmacological target in the treatment of several clinical conditions, including depression and anxiety. Serotonin-selective reuptake inhibitors and tricyclic antidepressants are the most predominantly prescribed drugs in the treatment of depression. In addition to antidepressants also psychostimulants, like cocaine and amphetamines, are important SERT antagonists. In the present study, we report the cloning and characterization of chicken SERT. Although the uptake kinetic was very similar to human SERT, the pharmacological profiles differed considerably for the two species. We find that chicken SERT is capable of discriminating between different serotonin-selective reuptake inhibitors; thus, the potency of S-citalopram and paroxetine is reduced more than 40-fold. A cross-species chimera strategy was undertaken and followed by species-scanning mutagenesis. Differences in pharmacological profiles were tracked to amino acid residues 169, 172, and 586 in human SERT. Structure-activity studies on structurally related compounds indicated that species divergences in drug sensitivity between human and chicken SERT were arising from differences in coordination or recognition of an important aminomethyl pharmacophoric substructure, which is shared by all high affinity antidepressants. Consequently, we suggest that Ala 169 and Ile 172 of human SERT are important residues in sensing the N-methylation state of SERT antagonists.
magnitude and duration of signaling and thus plays a key role in the spatio-temporal fine tuning of serotonergic neurotransmission.
Malfunction in active 5-HT reuptake is speculated to be associated with psychiatric disorders, particularly anxiety and depression (1, 2) . Antidepressants inhibiting 5-HT reuptake are used also in treatment of anxiety disorders, obsessivecompulsive disorders, and eating disorders (3, 4) .
SERT is a member of a large family of homologous integral membrane proteins (5) . SERT is of considerable interest as a molecular target for many antidepressants, including the tricyclic antidepressants such as imipramine and amitriptyline, as well as the serotonin-selective reuptake inhibitors (SSRIs) like citalopram, fluoxetine, paroxetine, sertraline, and fluvoxamine. SERT is also target for drugs of abuse including cocaine and amphetamines such as 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy") (6, 7) .
SERT is a putative 12-transmembrane (TM) domain protein that co-transports one 5-HT molecule inwardly, in a protonated form, together with one Na ϩ ion and one Cl Ϫ ion. An internal K ϩ ion is bound and countertransported, after dissociation of 5-HT, Na ϩ , and Cl Ϫ , as SERT returns to its initial state (8) . Although the stoichiometry of 5-HT transport predicts an electroneutral process, electrophysiological studies have revealed a net inward current, which probably arises from an uncoupled excess inward flux of Na ϩ ions (9, 10). The three-dimensional structure of SERT is unknown; however, in the quaternary structure SERT was reported to form homo-oligomeric complexes. This was supported by fluorescence resonance energy transfer interactions, chemical crosslinking, and co-immunoprecipitation of epitope-tagged SERT (11) (12) (13) .
Although the cloning of SERT cDNAs from several different species and their expression in heterologous systems has intensified characterization of recombinant SERT, the molecular mechanisms underlying transport and how it is inhibited are still not well understood (14 -26) . Interspecies differences in pharmacological profiles, combined with construction of crossspecies chimeras and site-directed mutagenesis, have been used as a rational strategy to localize domains and residues critical for ligand interaction. Studies using this strategy identified Phe 586 in TM12 to be important in high affinity recognition of tricyclic antidepressants (27, 28) , and in a similar study an important determinant of species-selective recognition of mazindol and citalopram was tracked to Tyr 95 in TM1 (29) . In one of our own species-scanning mutagenesis studies, we identified Met 180 in TM3 and Tyr 495 and Phe 513 , both in TM10, as important molecular determinants of antidepressant interactions (30) .
Site-directed mutagenesis studies have indicated that the conserved aspartate in TM1 of the monoamine transporters, Asp 98 in human SERT (hSERT), and the conserved serine in TM11, Ser 545 in hSERT, are both essential to transport activity, antagonist potency, and ion dependence (31, 32) . The important role of TM1 was supported by the suggestion of G100 as a structural pivot providing flexibility during substrate translocation (33) . In TM7, several residues are important for uptake and Na ϩ dependence, indicating that TM7 is involved in binding pocket formation or substrate translocation (34) . A cysteine scanning of residues in TM3 indicated that Ile 172 and Tyr 176 are associated with a 5-HT and cocaine binding pocket (35) .
A detailed mapping of residues defining the binding sites is, however, still incomplete, and details on transport dynamics and conformational changes during uptake are essentially unknown.
In the present study, we report the cloning of chicken SERT (gSERT). Although the amino acid sequence is highly conserved, the pharmacological characterization of a number of selected compounds revealed a profile very different from hSERT. Consequently, a species-scanning mutagenesis strategy was undertaken in order to identify residues that are important for differential binding of SSRIs.
MATERIALS AND METHODS
Dulbecco's modified Eagle's medium, fetal bovine serum, trypsin, and penicillin/streptomycin were purchased from Invitrogen. Cell culture flasks and 96-well plates were from NUNC. White 96-well culture plates and MicroScint-20 scintillation mixture were from Packard. ) . The QuikChange mutagenesis kit was from Stratagene. Restriction enzymes were purchased from New England Biolabs. The Rapid DNA ligation kit and Fugene-6 transfection reagent were from Roche Molecular Biochemicals. The Wizard PureFection plasmid DNA purification system was from Promega, and the ABI Prism BigDye terminator cycle sequencing ready reaction kit was from PerkinElmer Life Sciences. RTI-55 and short imipramine were a gift from Dr. Mikael Bols (Aarhus University, Denmark). S-and R-citalopram, S-didemethylcitalopram, and Lu 33-086-O, Lu 08-052-O were a gift from H. Lundbeck A/S. DASB was a gift from Dr. S. Houle (Vivian M. Rakoff PET Centre, Toronto, Canada). IDAM was a gift from the University of Pennsylvania Medical Centre (Philadelphia, PA).
Cloning of gSERT cDNA-Total RNA was isolated from chicken brain tissue using the acid guanidinium thiocyanate method by Chomczynski and Sacchi (36) . Single-stranded cDNA was synthesized from 5 g of total RNA using Superscript II reverse transcriptase (Invitrogen) and the gSERT gene-specific primer KR5 (CGTTGAATTGCTTG-GATAG) at 42°C for 50 min. Complementary RNA was removed with RNase H.
Full-length cDNA was cloned by PCR using primers KF1 with an integrated XhoI restriction site (CCGCTCGAGGGCAGGAGAAACCTT-GGAA) and KR3 with an integrated XbaI restriction site (CTAGTCTA-GACCAAATGTCCGTTGTCAGTG) located in the 5Ј-and 3Ј-untranslated region, respectively. The proofreading polymerase PFU Turbo (Stratagene) was used with the following touchdown PCR parameters: 30 s at 94°C, 30 s at 61°C, 150 s at 72°C for 25 cycles where the annealing temperature was decreased 0.4°C for every cycle followed by 35 cycles of 30 s at 94°C, 30 s at 51°C, and 150 s at 72°C. The resulting fragment was 2200 bp, which was the expected size based on the information from the chicken expressed sequence tags and the hSERT. The fragment was digested with XhoI and XbaI and inserted into the eucaryotic expression vector pcDNA 3 (Invitrogen) cleaved with the same enzymes. The PCR amplification was repeated in an independent experiment, and a total of eight clones were sequenced in their entirety to identify possible PCR-generated artifacts. Sequencing was performed using BigDye Terminator version 3.1 and an automated ABI 3100 Genetic Analyzer (Applied Biosystems).
The final clone contained 21 bp of 5Ј-untranslated region, the entire coding sequence, and 128 bp of 3Ј-untranslated region.
Construction of SERT Chimeras and Mutants-A PCR-based approach was chosen to generate rationally designed cross-species chimeras between hSERT and gSERT based on the method by Kirsch and Joly (37) . The coding region of hSERT was previously cloned from human placenta and inserted into the pcDNA3 vector, denoted hSERT (33) . Briefly, a region of the hSERT was amplified by PCR using primers complementary to hSERT in the 3Ј-end and complementary to gSERT in the 5Ј-end. The resulting fragment was gel-purified and subsequently used as a pair of complementary megaprimers following the QuikChange protocol (Stratagene). All chimeras were sequenced in their entirety to verify sequence switching points and exclude PCRgenerated errors. Primer sequences for the generation of megaprimers are as follows (5Ј to 3Ј direction): 1F, GATGGAGCTGGGAGACCGG-GAGACCTGGGGCAAGAAG; 1R, CATATTTTTCTCCAAATTGAAAT-GCATCCATTTCGGTGG; 2F, CAGGAATGGGTGTATTTCAATATGG-AGGAAAATCTGCCCG; 2R, CCACCTTGCCAGATGTCTTGACGCCT-TTCCAGATGC; 3F, CTGGAAAGGGGTCAAAACCTCTGGCAAGGTG-GTGTG; 3R, CTTGGTAGCAGTTGTTATTGAACTTGTTGTAGCTAGC; 4F, CAGCTACAACAAATTCCACAACAACTGCTACCAAGATGC; 4R, GGAATTCATCCAGTACTCCCGTGATCACCCCCTCCAAG; 5F, GATT-AGAGGGAGTGATTACTGCTGTGCTGGATGAGTTCCC; 5R, GTACC-AGCCTGGAGCGAAGCCGAGCATTTCCTTCAC; 6F, GAAAGAAATG-CTGGGCTTCAGCCCGGGGTGGTTCTGG; 6R, GAATACGCTCCTTA-AGTGTCCCTGGAGTGATGATCAAC; 13R, CGTGAAGGAGGACACG-AGGTAGTATAGCGCCCAGGCC; 14F, GCGTGGGTCTTCTACTACC-TCATCTCCTCCTTCACGG; 14R, GCCAGCTAATGCCCCCCAGGTCC-TGGAGCCCC; 15F, GGGCTGGATGACCTGGGGGGCATCAGCTG-GC; 16R, GGGATAGTTGTAATCAAAAAGTCGTAGTTGTGGCGGG-CTC; 17F, CCCCCCCGAGCTCCGGCTTTTCCAATATAATTATCCT-TAC. Primer combinations used to generate the megaprimers for crossspecies chimera constructions are shown in Table I .
The following single mutations were introduced in gSERT: F203Y, D209A, V212I, and I626F. The following double and triple mutations were introduced in gSERT and hSERT: gSERT D209A/V212I, gSERT D209A/L210F, gSERT L210F/V212I, gSERT V223A/F224L, gSERT D209A/L210F/V212I, gSERT D209A/V212I/I626F, and hSERT A169D/ I172V/F586I. All mutations were created using the QuikChange mutagenesis kit (Stratagene) according to the manufacturer's recommendations. The entire coding region was sequenced in all mutants.
Cell Culture and Expression of SERTs in COS-1 Cells-COS-1 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum, 100 g/ml streptomycin, and 100 units/ml penicillin at 37°C and 5% CO 2 in a humidified atmosphere.
For transfections, 0.2 g of plasmid and 0.4 l of Fugene6 (Roche Molecular Biochemicals) was used per cm 2 of plating area. Appropriate amounts of plasmid and Fugene6 were mixed with Dulbecco's modified Eagle's medium according to the manufacturer's recommendations. COS-1 cells were trypsinized and suspended in growth media, and the plasmid/Fugene6 mixture was added followed by dispension into growth plates at 70 -80% confluence. White 96-well plates (Corning) were used for uptake experiments.
5-HT Uptake Assays-Uptake assays were performed 40 -64 h after transfection. The medium was removed, and the cells were washed with phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na 2 HPO 4 , 1.4 mM KH 2 PO 4 , pH 7.4) containing 0.1 mM CaCl 2 and 1 mM MgCl 2 (PBSCM). Following washing, cells were incubated at room 3 H]5-HT concentration of 100 nM. The uptake was allowed to continue for 10 min at room temperature and terminated by washing with PBSCM. All washing steps were carried out using an automated plate washer. Following uptake, cells were solubilized in scintillant (MicroScint-20; PerkinElmer Life Sciences), and plates were counted in a Packard TopCounter NXT microplate scintillation counter. Specific uptake was determined as the difference between uptake counts from cells transfected with SERT-containing constructs and mock-transfected cells. Assuming Michaelis-Menten kinetics, the data were plotted and analyzed by nonlinear least-squares curve fit (GraphPad Prism). IC 50 values were calculated by nonlinear regression analysis of inhibition of normalized 5-HT uptake versus logarithmic drug concentration (GraphPad Prism). K i values were calculated from the IC 50 values using the Cheng and Prusoff equation (38) to adjust for substrate concentration. 95% confidence intervals for K i values were calculated (Graphpad Prism). K i values were compared using an unpaired t test (Graphpad Prism).
RTI-55 Binding Assays-COS-1 cells were transfected as described. Cells were grown for 64 h, and prior to harvesting, dishes were rinsed in PBS. Cells were harvested with a cell scraper in buffer 1 (50 mM Tris-base, 150 mM NaCl, 20 mM EDTA, pH 7.4). After centrifugation, cells were suspended and homogenized with an Ultra-turrax homogenizer for 20 s in buffer 1. Membranes were pelleted by ultracentrifugation, and homogenization was repeated. Finally, after ultracentrifugation, membranes were suspended in buffer 3 (50 mM Tris-base, 120 mM NaCl, 5 mM KCl, pH 7.4) and stored at Ϫ80°C. Membrane protein concentration was determined by the BCA protein assay reagent kit (Pierce). For IC 50 determinations, 2 g of membrane in buffer 3 was added to each well in a 96-well plate and combined with buffer 3 containing increasing concentrations of the desired drug and a final concentration of 200 pM [
125 I]RTI-55 (␤-carbomethoxy-3␤-(4-iodophenyl)tropane) as radioligand. Membranes were incubated for 60 min at room temperature and subsequently washed six times with water after transferring to a 96-well glass fiber filter plate GF/B (Unifilter; Packard Bell) preincubated with 50 l of 0.5% polyethyleneimine, using a Packard Bell cell harvester. Filters were soaked with 40 l of MicroScint 20 scintillation liquid (Packard Bell), and accumulated radioactivity per filter was determined by direct counting of plates using a Packard Bell microplate scintillation counter. IC 50 values were calculated as described for uptake inhibition. 
RESULTS
Cloning of a Chicken 5-HT Transporter-Initial 5-HT uptake inhibition experiments using synaptosomes prepared from chicken (Gallus gallus domesticus) brain indicated that the pharmacological properties of this transporter differed from the human counterpart. To study the molecular mechanisms underlying these differences in a cultured cell model, we cloned the gSERT. We used the hSERT cDNA sequence to search GenBank TM for possible chicken sequences encoding SERT. This search revealed several homologous chicken expressed sequence tag fragments, some of which contained apparent 5Ј-and 3Ј-nontranslated regions. We used the nontranslated sequences to design sequence-specific primers for reverse transcription and PCR. Using RNA extracted from chicken brain tissue as a template, we cloned gSERT into the mammalian expression vector, pcDNA3. We sequenced eight independent full-length cDNA clones from which we constructed a consen- sus sequence (GenBank TM accession number AY573844). The consensus sequence revealed an open reading frame of 2010 bp, which translates into a 670-amino acid protein. gSERT shows a high degree of similarity to the hSERT with an overall identity of 77% (Fig. 1) . The main difference between the SERT from the two species is observed in the predicted intracellular N terminus of the protein, which is 40 amino acids longer for gSERT compared with hSERT. Hydropathy analysis with TMHMM (available on the World Wide Web at www.cbs.dtu.dk/services/ TMHMM) predicts 12 transmembrane domains with intracellular N and C termini as described for other transporters of this family. Two potential N-glycosylation sites are present in the large second extracellular loop at Asn 248 and Asn 257 , corresponding to the sites previously identified in rat SERT (rSERT) and human norepinephrine transporter (39, 40) . Two cysteine residues, which form a potential disulfide bridge in the rSERT, are also conserved in gSERT (Cys 240 and Cys 249 ). Protein kinase C-dependent phosphorylation of hSERT is prevented by transporter substrates, whereas cocaine and antidepressants permit phosphorylation and subsequent internalization of hSERT (41) . To assess the possibility that gSERT can be phosphorylated, we used the neural network-based NetPhos 2.0 phosphorylation site prediction tool (available on the World Wide Web at www.cbs.dtu.dk/services/NetPhos/) to analyze the gSERT amino acid sequence for potential phosphorylation sites. NetPhos predicted that gSERT contains 26 potential phosphorylation sites (nine serines, 12 threonines, and five tyrosines), 16 643 ) is located in the putative C-terminal tail of the gSERT.
5-HT Uptake and Pharmacology of gSERT Compared with
hSERT-When transiently transfected in COS-1 cells, the cloned gSERT displayed robust and saturable 5-HT uptake, with an apparent affinity constant, K m , of 846 Ϯ 90 nM, which is comparable with values obtained for hSERT (Table II and Fig. 2) . V max values varied with transfection efficiencies, but in individual experiments, gSERT gave rise to slightly higher uptake than hSERT as demonstrated by the example in Fig. 2 .
The pharmacological profiles of gSERT and hSERT in inhibition studies on 5-HT uptake and RTI-55 binding were established and compared, using transiently transfected COS-1 cells or cell membranes prepared from transfected COS-1 cells.
We estimated the inhibitory potency of several SERT antagonists and substrates (Table III, Fig. 3) ; the five classical SSRIs paroxetine, S-citalopram, sertraline, fluoxetine, and fluvoxamine; the highly SERT-selective emissions tomography ligands DASB and IDAM; the tricyclic antidepressants imipramine and desipramine; the serotonin norepinephrine reuptake inhibitor venlafaxine; cocaine and the high affinity cocaine analog RTI-55; S-citalopram analogues R-citalopram, S-didemethylcitalopram, Lu 33-086-O, and Lu 08 -052-O; an imipramine analog, short imipramine, with a shorter alkylamine chain; dopamine; and finally the substrates MDMA and 5-HT.
The relative potencies of antagonists and substrates, comparing gSERT and hSERT, were very similar between uptake and binding inhibition, although the absolute K i values for individual compounds differed. The potency for some, but not all, compounds was different comparing gSERT and hSERT, and consequently a species-specific rank order potency profile was established (Table III) .
The five compounds with the highest potency at hSERT during 5-HT uptake inhibition studies were DASB, RTI-55, paroxetine, IDAM, and S-citalopram with mean K i values of 2.4, 8.2, 9.7, 11, and 13 nM, respectively. In comparison, for gSERT the five highest ranking compounds were DASB, RTI- In RTI-55 binding inhibition studies, the compounds with highest potency for hSERT were paroxetine, DASB, sertraline, RTI-55, and S-citalopram, with mean K i values of 0.62, 0.89, 1.6, 2.1, and 7.1 nM, respectively, and for gSERT the highest ranking were DASB, RTI-55, sertraline, fluvoxamine, and venlafaxine, with mean K i values of 1.0, 2.3, 4.6, 29, and 38 nM, respectively.
Noticeably, the inhibitory potency of paroxetine, S-citalopram, IDAM, and imipramine is more than 10-fold reduced for gSERT compared with hSERT in both inhibition of 5-HT uptake and inhibition of RTI-55 binding by comparing the respective K i values (Table III) . In particular, for S-citalopram and paroxetine the difference is evident, since the potency at gSERT is more than 40-fold reduced. The inhibitory potency of sertraline, fluoxetine, desipramine, and Lu 08-052-O is slightly reduced for gSERT. The inhibitory potency of fluvoxamine, DASB, venlafaxine, R-citalopram, S-didemethylcitalopram, Lu 33-086-O, and short imipramine is unchanged between gSERT and hSERT. Cocaine displays higher affinity for gSERT compared with hSERT. Dopamine and the two substrates MDMA and 5-HT show no difference between gSERT and hSERT, thus confirming the affinity measurements for 5-HT uptake.
Identification of TM3 and TM12 as Determinants for High Affinity S-Citalopram and Paroxetine Recognition Using
Crossspecies Chimeras-In order to identify regions of SERT that are essential for the observed differences in drug sensitivity, we designed a number of cross-species chimeras of gSERT and hSERT. We used a restriction site-independent method (37) to rationally generate a number of chimeras, in which successive parts of gSERT were exchanged with the corresponding parts of hSERT (Fig. 4) . We initially constructed a set of 12 chimeras, labeled chimeras 1-12. K m and V max values for 5-HT uptake for all chimeras were within 2-fold of the parental gSERT and hSERT. Since we observed the largest differences in potencies for S-citalopram and paroxetine, we decided to initially focus on these two drugs. Consequently, we determined the S-citalopram and paroxetine potencies for the chimeras in 5-HT uptake inhibition studies performed in parallel with the wild type gSERT and hSERT, using transiently transfected COS-1 cells. The results of these experiments are shown in Fig. 5, A and B. We found that for paroxetine, chimeras 2, 7, 8, and 10 display near hSERT phenotype. These chimeras all share the TM3-TM4 region of hSERT, indicating that residues within this region are essential for the high affinity recognition of paroxetine. For Scitalopram, things were less clear, but the results from chimeras 6 -8 suggest that there is an additive effect of the TM11-TM12 region and more proximal parts of the SERT molecule.
To further pinpoint the regions of the SERT protein involved in recognition of paroxetine and S-citalopram, we created five additional chimeras. We constructed chimeras 13-15, which exchange the gSERT TM3, the large extracellular loop 2, or the TM4 region, respectively, with the corresponding hSERT regions. The chimeras 16 and 17 exchange gSERT TM11 or TM12 for the corresponding hSERT regions. When we tested the potency of paroxetine and S-citalopram on these chimeras, we observed a drastic increase in potency for chimeras 13 and 17, whereas chimeras 14 -16 remained unchanged compared with gSERT (Fig. 5) .
In conclusion, our work with cross-species chimeras demonstrates that residues in the TM3 and TM12 regions are important for conferring high affinity recognition of S-citalopram and paroxetine.
The gSERT Triple Mutant D209A/V212/I626F Gains High Affinity for Antagonists-A total of six amino acid residues diverge between gSERT and hSERT in the target TM3 region exchanged in the chimera 13. Using site-specific mutagenesis, we substituted gSERT amino acids for the corresponding hSERT residues to identify the amino acids responsible for the observed gain in antagonist sensitivity in chimera 13. We thus created the following gSERT mutants: F203Y, D209A/V212I, D209A/L210F, L210F/V212I, V223A/F224L, and D209A/ L210F/V212I. Only mutants containing either D209A or V212I displayed an increase in S-citalopram and paroxetine sensitivity compared with WT gSERT (Fig. 6, A and B) . The effect of D209A and V212I appears additive and is not potentiated by mutating the neighboring Leu 210 residue. The paroxetine and the S-citalopram affinity for the double mutant D209A/V212I resembles that of chimera 13.
Eight amino acids diverge in the stretch of amino acid sequence encompassing TM12, which is exchanged between gSERT and hSERT in the chimera 17. Barker and Blakely (28) previously reported that a single amino acid in TM12, Phe 586 , is involved in high affinity interactions of tricyclic antidepressants with the hSERT. The corresponding residue in gSERT is Ile 626 and thus differs from the hSERT counterpart. We considered the possibility that in the gSERT context this residue might be responsible for the gain in affinity of paroxetine and S-citalopram observed for the chimera 17. Indeed, when we compared the gSERT I626F mutant with chimera 17 in 5-HT uptake inhibition assays with paroxetine and S-citalopram, we found that they closely resembled each other (Fig. 6, C and D) .
Based on these results, we considered whether a gSERT triple mutant D209A/V212I/I626F would completely recover high affinity for paroxetine and S-citalopram and whether the corresponding hSERT triple mutant, A169D/I172V/F586I, would lose high affinity. As displayed in Fig. 7 the gSERT D209A/V212I/I626F attains near hSERT affinity for paroxetine and S-citalopram, whereas the hSERT A169D/I172V/F586I shifts to gSERT affinity. The affinity for fluvoxamine and serotonin, however, does not change significantly, implying that the overall conformation is intact in the mutants.
We next undertook a more thorough investigation, where we tested the single gSERT mutants D209A, V212I, and I626F, the double mutant D209A/V212I, and the triple mutant D209A/V212I/I626F against the panel of compounds we initially used to screen WT hSERT and gSERT, using both 5-HT uptake inhibition and RTI-55 binding inhibition assays. This was done in order to test whether the gSERT mutations affect the affinities of other compounds than paroxetine and S-citalopram. The results for inhibition of 5-HT uptake and inhibition of RTI-55 binding are presented in Tables IV and V, respectively. As observed from the studies on the WT gSERT and hSERT, there is good agreement between the results from 5-HT uptake inhibition and RTI-55 binding inhibition. Although the absolute K i values may differ, the relationship between mutants is generally the same in the two assays. The gSERT D209A/V212I/I626F mutant acquires hSERT affinities for IDAM and imipramine. For IDAM, the gain of affinity arises primarily from the combined mutation of D209A and V212I; the I626F mutation does not gain much in affinity, nor does the D209A/V212I mutant gain much affinity by the addition of I626F. For imipramine, the single mutants I626F and V212I contribute the largest gain in affinity, with little additive effect from the D209A mutation, which is also true for the two other tricyclics, short imipramine and desipramine. It is also noteworthy that the affinities for the latter two drugs are even higher for the gSERT mutants than for either gSERT or hSERT WT. For sertraline, fluoxetine, and Lu 08-052-O, the difference between WT hSERT and gSERT was about 5-fold for uptake inhibition, and for fluoxetine and Lu 08-052-O in particular, we observed a gain in function for the gSERT triple mutant D209A/V212I/ I626F. For all other compounds, the differences between WT hSERT and gSERT were less than 2-fold and, in most cases, were insignificant. Data on the mutants show that they generally possess affinities in the same range.
DISCUSSION
In the present study, we report the cloning of a SERT from chicken brain, gSERT, thus representing the first cloned SERT from the Aves class of the Cordata phylum. The amino acid sequence of this transporter was very similar to the hSERT. In accordance with SERTs from other nonmammalian species, the main differences were located in the intracellular amino terminus. gSERT conferred high affinity and saturable 5-HT uptake in transiently transfected COS-1 cells with kinetic parameters similar to hSERT. The pharmacological profile of gSERT was, however, distinctly different from that of hSERT with respect to antagonist potency in 5-HT uptake assays as well as RTI-55 binding studies. Most prominent was the observation that when testing the potency of eight highly selective SERT antagonists, the affinities for gSERT were severalfold lower for paroxetine, S-citalopram, S-desmethylcitalopram, and IDAM and a few-fold lower for fluoxetine and sertraline, whereas no differences in potencies were observed for fluvoxamine and DASB, compared with hSERT. The potency of imipramine was also considerably lower for gSERT than for hSERT. Taken together, our data indicate that whereas the affinity is specifically decreased more than 40-fold for some drugs, the overall conformation is unlikely to be compromised in gSERT, since uptake kinetic and affinity for particular drugs is unaffected.
When comparing K i values obtained from 5-HT uptake inhibition and RTI-55 binding inhibition studies (Table III) , we found that the absolute potency of many drugs differed between these two assays, although the relative potency, comparing gSERT and hSERT, was nearly identical. For antagonists, the potency for inhibiting RTI-55 binding was generally higher than the potency for inhibiting 5-HT uptake. Such differences have also been noted in other studies (42) . The difference in absolute K i values may be due to SERT being arrested in one particular conformation during RTI-55 binding, whereas SERT during the 5-HT uptake process may undergo a number of different conformations.
We used a cross-species chimera strategy to identify TM3 and TM12 as being involved in conferring high affinity paroxetine and S-citalopram binding. Site-directed mutagenesis revealed that mutating Asp 209 and Val 212 in the gSERT, corresponding to 169 and 172 in the hSERT, to their cognate hSERT identities partly restored paroxetine and S-citalopram potencies to that obtained at hSERT. Combining these mutants with the I626F mutation in TM12 yielded antagonist potencies comparable with hSERT for paroxetine and S-citalopram as well as other antagonists. A common trend for desipramine and short imipramine is that the gSERT D209A/V212I/I626F mutant acquires higher affinity for these compounds than for either hSERT or gSERT WT. This suggests that gSERT contains residues that allow for more favorable recognition of tricyclics than does the hSERT. Mapping of these residues would generate more information on the architecture of the SERT antagonist binding pocket.
The TM3 region of the SERT has been proposed to line a translocation pore with residues 169, 172, 176, and 179 facing a 5-HT-and cocaine-binding pocket (35) . These observations are in good agreement with the results we have presented in this report and highlight the importance of this region in substrate transport as well as antagonist recognition.
Looking at the discrimination of antagonists for gSERT compared with hSERT, it is tempting to compare antagonist structures and search for common features to explain the differences in potency observed for antagonists on gSERT and hSERT. Whereas it is beyond the scope of this report to perform an extensive structure modeling analysis, a previous pharmacophore modeling study of SSRIs has been reported (43) . In this study, three fix points were used for superimposition of low energy conformations of citalopram, fluoxetine, paroxetine, and sertraline. Two points, each representing the centers of the two aromatic rings, and a point in the direction of the electronic lone pair 2.8 Å away from the basic nitrogen atom of the gSERT WT nM alkylamine tail of citalopram, fluoxetine, and sertraline and the piperidine nitrogen in paroxetine, respectively, were superimposed to generate a common pharmacophoric model. The site point was used to simulate an interaction with a hypothetical acidic residue, presumed to be the primary recognition site in the transporter molecule. Sertraline and fluoxetine lack one of the N-methyl groups. Consequently, they are less bulky in this part of the model. Our data show that the potencies of S-citalopram and paroxetine are greatly reduced for gSERT. The potency of sertraline and fluoxetine, on the other hand, are only slightly reduced compared with hSERT. No species difference in potency was observed for S-citalopram analogues S-didesmethylcitalopram and Lu 33-086-O, which lacks both N-methyl groups or has a shorter tail length, respectively (i.e. absence of one or both N-methyl groups or dislocation of the amino-dimethyl substructure reduces drug potency for hSERT but not for gSERT).
In structural terms, the majority of the activity data shown in Table III suggests that removing N-methyl groups reduces species divergences in drug potency. One exception is DASB, which has a similar affinity for the two species although possessing two N-methyl groups. Whereas DASB is structurally very similar to IDAM, their degrees of species selectivity differ. This is likely to be caused by their obvious divergences, which appear to overrule the effect of the N-methyl groups in conferring species selectivity.
According to our data, we suggest a model where the Ala 169 and Ile 172 in hSERT participate in the coordination of the common amino-methyl pharmacophoric substructure of S-citalopram and its counterpart in paroxetine, whereas only Ile 172 appears to be important for the recognition of sertraline and fluoxetine, which is in agreement with the fact that these two drugs only possess a single distal N-methyl group at the tail.
Also in agreement with the suggested model is that IDAM and imipramine, which both possess the dimethylamino group, both display diverging potency for hSERT and gSERT. On the other hand, we observed no species difference in sensitivity toward the low affinity compound R-citalopram, indicating that the alkylamine tail is coordinated much differently compared with S-citalopram. It is likely that the lower binding affinity of R-citalopram is caused by steric hindrance at the binding site preventing a favorable coordination of the tail.
In a previous study by Barker et al. (32) , Asp 98 in TM1 was suggested to interact with the alkylamine tail by formation of an ion pair to the protonated alkylamine nitrogen in 5-HT congeners. Our data indicate that two residues in TM3, Ala 169 and Ile 172 in hSERT, are important in sensing the N-methylation state of SERT inhibitors, and consequently our study suggests that these residues and Asp 98 from TM1, although distant in the primary sequence, are in close proximity in the tertiary structure. A recent model building of SERT based on the electron density projection map of the bacterial Na ϩ /H as important residues in antagonist binding and also support our suggestion of spatial constraints for these residues, which are located on nonadjacent TM domains (44) .
